Suppr超能文献

儿童弥漫性内在脑桥胶质瘤再放疗第二疗程:病例研究。

Second course of re-irradiation in pediatric diffuse intrinsic pontine glioma : A case study.

机构信息

Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

出版信息

Strahlenther Onkol. 2023 Aug;199(8):773-777. doi: 10.1007/s00066-023-02057-x. Epub 2023 Mar 2.

Abstract

PURPOSE

Concomitant chemoradiation followed by repeat (dose-deescalated) irradiation has become standard of care in treating childhood diffuse intrinsic pontine glioma (DIPG) during first line treatment and at first progression. Progression after re-irradiation (re-RT) is in most cases symptomatic and either treated systemically with chemotherapy or new innovative approaches including targeted therapy. Alternatively, the patient receives best supportive care. Data on second re-irradiation in DIPG patients with second progression and good performance status are sparse. This is a case report of second short-term re-irradiation to shed further light on this option.

METHODS

Retrospective case report of a 6-year-old boy with DIPG receiving a second course of re-irradiation (with 21.6 Gy) as part of an individual multimodal approach in a patient with very low symptom burden.

RESULTS

The second course of re-irradiation was feasible and well tolerated. No acute neurological symptoms or radiation-induced toxicity occurred. Overall survival was 24 months after initial diagnosis.

CONCLUSION

A second course of re-irradiation can be an additional tool in patients with progressive disease after first- and second-line irradiation. It is unclear whether and to what extent it contributes to progression-free survival prolongation and if-since our patient was asymptomatic-progression-associated neurological deficits can be alleviated.

摘要

目的

在一线治疗和首次进展时,同时进行放化疗,然后重复(剂量递减)放疗已成为治疗儿童弥漫性内在脑桥胶质瘤(DIPG)的标准治疗方法。在再次放疗(re-RT)后进展的情况下,大多数情况下是有症状的,可采用化疗或新的创新方法(包括靶向治疗)进行全身治疗。或者,患者接受最佳支持性护理。关于第二次进展且表现状态良好的 DIPG 患者接受第二次再放疗的数据很少。这是一例第二次短期再放疗的病例报告,旨在进一步探讨该选择。

方法

回顾性报告一名 6 岁男孩,患有 DIPG,在极低症状负担的患者中,作为个体化多模式治疗的一部分,接受第二次再放疗(21.6Gy)。

结果

第二次再放疗是可行的且耐受良好。未发生急性神经症状或放射性毒性。从初始诊断开始,总生存期为 24 个月。

结论

对于一线和二线放疗后疾病进展的患者,第二次再放疗可以是一种额外的治疗工具。目前尚不清楚它是否以及在多大程度上有助于延长无进展生存期,以及如果-因为我们的患者无症状-进展相关的神经功能缺损是否可以得到缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a077/10361911/b6e27f04f550/66_2023_2057_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验